ABIO.ME Stock Analysis
AB
Attractive
Based on Eyestock quantitative analysis, ABIO.ME`s fundamental data and valuation indicate an investment grade of Attractive at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Human Stem Cells Institute OJSC engages in the discovery, research, development, and marketing of proprietary products and services in the field of regenerative medicine, medical genetics, bio-insurance, gene therapy, and biopharmaceutics. The company is headquartered in Moscow, Moscow. The company went IPO on 2006-05-23. The firm is engaged in such projects as: Gemabank, cord blood stem cells bank; Gemascreen medical genetic diagnostics and consulting services provided by the Company domestically with the aim of early detection, treatment or prevention of inherited diseases; SPRS-therapy service a set of personalized diagnostics and treatment procedures; SynBio, which focuses on development of new medicines. In addition, the Company is a producer of Neovasculgen, a gene-therapy drug. In February 2014, it opened a biotech complex in Kyiv.